Real estate agent Kirsten Jordan breaks down the latest trends in the housing market, near-record home sale cancellations in April and her outlook on mortgage rates. Myasthenia gravis is a rare, ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

As such, UCB’s recently-debuted, U.S.-based DTC rare-disease campaign Imagine Your Zillions supports its gMG treatment Zilbrysq. The effort is based on flipping the preconceived notions associated ...

GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, closed an oversubscribed $130 million Series B financing. The ...

Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program through clinical proof-of-concept and the continued advancement of the company’s differentiated ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of ...